Drug Pipeline

zamtocabtagene autoleucel (MB-CART2019.1) Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
5
Active Studies
4
Recruiting
1
Top Sponsors
Active Studies by Phase
Phase 2
3
Phase 1/2
1
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT07288879 DALY II Japan/MB-CART2019.1 for DLBCL DLBCL - Diffuse Large B Cell Lymphoma Recruiting
NCT06508931 Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric… B-Cell Neoplasm Recruiting
NCT07569965 Frontline Risk-Adapted Optimization of Novel Targeted Immunotherapy Evaluation in… Mantle Cell Lymphoma (MCL) Not Yet Recruiting
Phase 1/2
NCT07178431 MB-CART2019.1 in Refractory Multiple Sclerosis Multiple Sclerosis Recruiting
Phase 1
NCT06708845 US Zamto-cel Autoimmune Diseases Lupus Nephritis Recruiting
Sponsors Running zamtocabtagene autoleucel (MB-CART2019.1) Trials
Miltenyi Biomedicine GmbH (5)
Disease Areas
Lupus (SLE) (1) Scleroderma (1) Multiple Sclerosis (1) DLBCL (1) Mantle Cell Lymphoma (1)
Get alerts when zamtocabtagene autoleucel (MB-CART2019.1) trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free